Thursday, 18 Oct 2018

You are here

Vitamin D Insensitivity in the Rheumatoid Joint

Researchers from the University of Birmingham have shown that while Vitamin D may be effective at preventing the onset of inflammation, it is less effective once inflammatory disease is established - largely because, once established, rheumatoid arthritis leads to vitamin D insensitivity. (Citation source https://buff.ly/2iGHYmI)

Another key finding of the research was that the impact of vitamin D on inflammatory disease cannot be predicted using cells from healthy individuals or even from the blood of patients with inflammation as cells from the diseased tissue behave in a very different way.

In addition to its well-established actions on the skeleton, vitamin D is a potent modulator of the immune system. In particular, vitamin D can suppress inflammation in autoimmune diseases such as rheumatoid arthritis. Patients with rheumatoid arthritis are frequently vitamin D deficient and may receive vitamin D supplementation.

1,25-dihydroxyvitaminD3 (1,25(OH)2D3), has potent anti-inflammatory effects, including suppression of IL-17 + and IFNγ+ T cells. They studied cells from paired peripheral blood and synovial fluid (SF) samples patients with active RA. Specifically they sought to assess cellular responses to the active form of vitamin D.

Overall theyfound that cells taken from the joints of RA patients were much less sensitive to active vitamin D. 1,25(OH)2D3 had significantly less suppressive effect on Th17 cells (IL-17+IFNγ-) and Th17.1 cells (IL-17+IFNγ+) from SF compared to those from blood, and had no effect on SF CD4+ or CD8+ IFNγ+ T cell frequencies. Memory T cells (CD45RO+) predominate in SF, and 1,25(OH)2D3 had less effect on memory T cells relative to naïve (CD45RA+) T cells.

Thus the potential anti-inflammatory effects of vitamin D in active RA are impaired because of reduced effects on phenotype-committed, inflammatory memory T cells that are enriched in SF. (Such cells are already overcommitted to inflammation)

Researchers postulated that much higher doses of vitamin D may be needed to overcome the vitamin D insensitivity within the joint. Restoration of 1,25(OH)2D3 responses in memory T cells, by whatever means,  may provide a new strategy for treatment of inflammatory diseases such as RA. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Predictive Risk Factors for Uveitis in JIA

Researchers from Germany have studied a large cohort of juvenile idiopathic arthritis (JIA) patients and shown that JIA disease activity scores and laboratory biomarkers could be used to better define the group of JIA patients at high risk of uveitis onset.

Elder Rheumatoids Less Likely to Receive Biologics

Multiple studies have shown that elderly rheumatoid arthritis (RA) patients tend to be under-treated and receive DMARD therapies less often than younger RA patients. Now a VAMC study shows that the elderly are less likely to receive biologic agents yet are as likely to be subjected to glucocorticoid use.

Long-Term Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis

Only inhibitors of IL-1 (canakinumab) and IL-6 (tocilizumab) are FDA approved for use in children with systemic onset juvenile idiopathic arthritis (sJIA). Now, long-term data from the extension studies from two phase III studies shows that canakinumab yields long-term improvements with reduced glucocorticoid dosing with no new safety findings with long-term use.

Defining Refractory Rheumatoid Arthritis

Researchers from the British Society for Rheumatology Biologics (BSRBR) set out to define under what circumstances will rheumatoid arthritis (RA) patients manifest biologic disease-modifying antirheumatic drugs (bDMARDs) refractory disease.

Using the patients from the BSRBR Register (2001 to 2014) they defined patients as bDMARD refractory when they initiated their third class of bDMARD.

Venous Thromboembolism Increased with Rheumatoid Arthritis, Not with TNF Inhibition

Venous thromboembolism (VTE) is a common adverse event throughout medicine and includes both pulmonary embolism (PE) and deep vein thrombosis (DVT).   The cost of diagnosing a thromboembolic event is approximately $4000 - $5550, while the annual cost of treating one case of VTE is between $17,000 and $19,000. The impact of VTE is substantial.